The data indicated that patients with high MED1 expression levels (Figure 1d) or low miR-205 expression levels (Figure 1e) in tumors had much worse distant relapse-free survival than those with low MED1 expression levels or high miR-205 expression levels in Erα-positive breast cancer patients treated with tamoxifen therapy. This evidence concerns the gene ESR1 and breast cancer.